--- title: "SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 39.57 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/280775727.md" datetime: "2026-03-27T10:53:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280775727.md) - [en](https://longbridge.com/en/news/280775727.md) - [zh-HK](https://longbridge.com/zh-HK/news/280775727.md) --- # SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 39.57 M Revenue: As of FY2025 Q4, the actual value is USD 39.57 M. EPS: As of FY2025 Q4, the actual value is USD 0.14. EBIT: As of FY2025 Q4, the actual value is USD 12.91 M. ### Fourth Quarter 2025 Highlights (Three Months Ended December 31, 2025) #### Revenue - Total revenues were $40 million, representing an 11% year-over-year decrease. #### Profitability - Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. - EBITDA was $14 million, representing a 35% year-over-year decrease. - EBITDA margin was 34% for the fourth quarter of 2025, representing a year-over-year decrease of 12 percentage points. - Return on equity was 23%, representing a year-over-year increase of 9.8 percentage points. - Net income margin was 36%. #### Operational Metrics - The number of Franchise Locations was 283 as of December 31, 2025, an increase of 34 locations from December 31, 2024. - The number of customers in the last twelve months ended December 31, 2025, was 6.6 million, representing a 12% year-over-year increase. - The repeat rate for customers who visited franchisee’s clinics twice or more was 72%. - Average revenue per customer recovered to $316, an 11% increase year over year. ### Full Year 2025 Highlights (Twelve Months Ended December 31, 2025) #### Revenue - Total revenues were $174 million, representing a 15% year-over-year decrease. #### Profitability - Net Income attributable to SBC Medical Group was $51 million, representing a 9% year-over-year increase. - EBITDA was $70 million, representing a 21% year-over-year decrease. - EBITDA margin was 40% for the full year 2025, representing a year-over-year decrease of 3 percentage points. - Net income margin expanded from 23% to 29%. #### Detailed Financials (Full Year 2025 vs. 2024) - **Total revenues, net:** $173,607,489 in 2025 compared to $205,415,542 in 2024. - **Cost of revenues:** $46,323,767 in 2025 compared to $49,365,035 in 2024. - **Gross profit:** $127,283,722 in 2025 compared to $156,050,507 in 2024. - **Selling, general and administrative expenses:** $59,797,324 in 2025 compared to $57,665,140 in 2024. - **Stock-based compensation:** $0 in 2025 compared to $13,022,692 in 2024. - **Impairment loss on intangible asset:** $0 in 2025 compared to $15,058,965 in 2024. - **Total operating expenses:** $59,797,324 in 2025 compared to $85,746,797 in 2024. - **Income from operations:** $67,486,398 in 2025 compared to $70,303,710 in 2024. - **Net income:** $51,045,023 in 2025 compared to $46,689,892 in 2024. - **Net income attributable to SBC Medical Group Holdings Incorporated:** $50,985,613 in 2025 compared to $46,614,275 in 2024. #### Cash Flow (Full Year 2025 vs. 2024) - **Net cash provided by operating activities:** $24,668,496 in 2025 compared to $20,582,933 in 2024. - **Net cash used in investing activities:** -$20,971,552 in 2025 compared to -$10,102,410 in 2024. - **Net cash provided by financing activities:** $38,292,183 in 2025 compared to $22,965,400 in 2024. - **Cash and cash equivalents as of the end of the year:** $163,773,838 in 2025 compared to $125,044,092 in 2024. ### Outlook / Guidance SBC Medical is focusing on three key priorities for 2026: advancing its multi-brand strategy in dermatology, expanding its non-aesthetic healthcare portfolio, and building a stronger foundation in international markets. The company believes it is well-positioned to return to sustainable top-line growth, with the structural headwinds of the past two years largely behind it. ### Related Stocks - [SBCWW.US](https://longbridge.com/en/quote/SBCWW.US.md) ## Related News & Research - [SOC: Ramping up offshore production with robust cash flow and optimized capital structure](https://longbridge.com/en/news/295454306.md) - [Roth MKM Reaffirms Their Buy Rating on Sable Offshore (SOC)](https://longbridge.com/en/news/295458886.md) - [MEDSTORY•AI Builds Scientific Narratives That Are Both Defensible and Engaging in 90 Minutes Instead of Months](https://longbridge.com/en/news/294845814.md) - [Sable Offshore Corp. Reports Second Quarter 2026 Financial and Operational Results | SOC Stock News](https://longbridge.com/en/news/295453619.md) - [REG - Soc EnergElectricaSA - H12026 Preliminary Key Operational Indicators](https://longbridge.com/en/news/295424368.md)